Perspective Therapeutics, Inc.
US ˙ NYSEAM

Introduction

This page provides a comprehensive analysis of the known insider trading history of Juan Graham. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Juan Graham has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CATX / Perspective Therapeutics, Inc. Chief Financial Officer 35,354
US:FGEN / FibroGen, Inc. CHIEF FINANCIAL OFFICER 164,863
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Juan Graham. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CATX / Perspective Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CATX / Perspective Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-03-28 CATX Graham Juan 33,333 2.2484 33,333 2.2484 74,946 117 4.3500 70,054 93.47

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CATX / Perspective Therapeutics, Inc. Insider Trades
Insider Sales CATX / Perspective Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CATX / Perspective Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CATX / Perspective Therapeutics, Inc. Insider Trades
Insider Purchases FGEN / FibroGen, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CATX / Perspective Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FGEN / FibroGen, Inc. Insider Trades
Insider Sales FGEN / FibroGen, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CATX / Perspective Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-06-07 FGEN Graham Juan 1,050 16.9494 42 423.7350 17,797 156 0.3801 -17,780 -99.91
2023-06-07 FGEN Graham Juan 735 17.0383 29 425.9575 12,523
2023-03-10 FGEN Graham Juan 1,112 20.1973 44 504.9325 22,459
2023-03-10 FGEN Graham Juan 1,456 20.1973 58 504.9325 29,407
2023-03-10 FGEN Graham Juan 2,344 20.1973 94 504.9325 47,342
2023-03-08 FGEN Graham Juan 2,749 21.1559 110 528.8975 58,158
2022-12-09 FGEN Graham Juan 781 14.8900 31 372.2500 11,629

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FGEN / FibroGen, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Juan Graham as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-04-01 2025-03-28 4 CATX Perspective Therapeutics, Inc.
Common Stock
P - Purchase 33,333 35,354 1,649.33 2.25 74,946 79,490
2025-01-07 3 CATX Perspective Therapeutics, Inc.
Common Stock
2,021
2024-12-09 2024-12-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,066 164,863 -0.64 0.34 -365 56,400
2024-12-09 2024-12-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,446 165,929 -0.86 0.34 -495 56,764
2024-09-09 2024-09-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,065 167,375 -0.63 0.39 -415 65,276
2024-09-09 2024-09-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -16,050 168,440 -8.70 0.39 -6,260 65,692
2024-06-10 2024-06-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,182 184,490 -0.64 1.10 -1,300 202,939
2024-06-10 2024-06-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -17,797 185,672 -8.75 1.19 -21,178 220,950
2024-03-08 2024-03-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,181 203,469 -0.58 1.79 -2,114 364,210
2024-03-08 2024-03-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -422 204,650 -0.21 1.87 -789 382,696
2024-03-08 2024-03-06 4 FGEN FIBROGEN INC
Common Stock
A - Award 781 205,072 0.38
2024-03-08 2024-03-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -20,327 204,291 -9.05 1.87 -38,011 382,024
2024-02-23 2024-02-21 4 FGEN FIBROGEN INC
Common Stock
A - Award 52,000 224,618 30.12
2023-12-11 2023-12-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,085 172,618 -0.62 0.62 -668 106,229
2023-12-11 2023-12-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -15,573 173,703 -8.23 0.58 -9,032 100,748
2023-09-08 2023-09-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -1,096 189,276 -0.58 0.99 -1,088 187,913
2023-09-08 2023-09-06 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -711 190,372 -0.37 0.96 -685 183,347
2023-09-01 2023-08-30 4 FGEN FIBROGEN INC
Common Stock
A - Award 120,000 191,083 168.82
2023-06-09 2023-06-07 4 FGEN FIBROGEN INC
Common Stock
S - Sale -735 71,083 -1.02 17.04 -12,523 1,211,133
2023-06-09 2023-06-07 4 FGEN FIBROGEN INC
Common Stock
S - Sale -1,050 71,818 -1.44 16.95 -17,797 1,217,272
2023-03-10 2023-03-10 4 FGEN FIBROGEN INC
Common Stock
S - Sale -2,344 72,868 -3.12 20.20 -47,342 1,471,737
2023-03-10 2023-03-10 4 FGEN FIBROGEN INC
Common Stock
S - Sale -1,456 75,212 -1.90 20.20 -29,407 1,519,079
2023-03-10 2023-03-10 4 FGEN FIBROGEN INC
Common Stock
S - Sale -1,112 76,668 -1.43 20.20 -22,459 1,548,487
2023-03-10 2023-03-08 4 FGEN FIBROGEN INC
Common Stock
A - Award 4,668 77,780 6.38
2023-03-10 2023-03-08 4 FGEN FIBROGEN INC
Common Stock
A - Award 2,899 73,112 4.13
2023-03-10 2023-03-08 4 FGEN FIBROGEN INC
Common Stock
S - Sale -2,749 70,213 -3.77 21.16 -58,158 1,485,419
2023-02-23 2023-02-21 4 FGEN FIBROGEN INC
Common Stock
A - Award 25,000 72,962 52.12
2022-12-15 2022-12-08 4 FGEN FIBROGEN INC
Common Stock
S - Sale X -478 50,150 -0.94 15.47 -7,395 775,820
2022-12-15 2022-12-08 4 FGEN FIBROGEN INC
Common Stock
S - Sale X -5,263 50,628 -9.42 14.84 -78,103 751,320
2022-12-15 2022-12-12 4/A FGEN FIBROGEN INC
Common Stock
S - Sale X -1,407 47,962 -2.85 14.50 -20,402 695,449
2022-12-15 2022-12-09 4/A FGEN FIBROGEN INC
Common Stock
S - Sale -781 49,369 -1.56 14.89 -11,629 735,104
2022-12-14 2022-12-12 4 FGEN FIBROGEN INC
Common Stock
S - Sale X -1,407 53,703 -2.55 14.50 -20,402 778,694
2022-12-14 2022-12-09 4 FGEN FIBROGEN INC
Common Stock
S - Sale -781 55,110 -1.40 14.90 -11,637 821,139
2022-09-08 2022-09-07 4 FGEN FIBROGEN INC
Common Stock
F - Taxes -3,009 55,891 -5.11 12.62 -37,974 705,344
2022-02-16 2022-02-14 4 FGEN FIBROGEN INC
Stock Option (Right to Buy)
A - Award 37,500 37,500
2022-02-16 2022-02-14 4 FGEN FIBROGEN INC
Common Stock
A - Award 22,500 58,900 61.81
2021-09-09 3 FGEN FIBROGEN INC
Common Stock
1,400
2021-09-09 2021-09-07 4 FGEN FIBROGEN INC
Stock Option (Right to Buy)
A - Award 196,000 196,000
2021-09-09 2021-09-07 4 FGEN FIBROGEN INC
Common Stock
A - Award 35,000 36,400 2,500.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)